Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6759MR)

This product GTTS-WQ6759MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6759MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13189MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ481MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ2067MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ1406MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACA125
GTTS-WQ15238MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TAK-079
GTTS-WQ7776MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ15827MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ8522MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Hu3F8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW